Legacy Financial Advisors Inc. Has $879,000 Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Legacy Financial Advisors Inc. grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,976 shares of the medical equipment provider’s stock after purchasing an additional 101 shares during the period. Legacy Financial Advisors Inc.’s holdings in Intuitive Surgical were worth $879,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. Gilbert & Cook Inc. increased its stake in Intuitive Surgical by 6.5% during the 4th quarter. Gilbert & Cook Inc. now owns 3,437 shares of the medical equipment provider’s stock worth $1,160,000 after acquiring an additional 211 shares during the period. TrinityPoint Wealth LLC lifted its position in Intuitive Surgical by 21.5% during the fourth quarter. TrinityPoint Wealth LLC now owns 1,081 shares of the medical equipment provider’s stock worth $365,000 after purchasing an additional 191 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Intuitive Surgical by 7.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 854 shares of the medical equipment provider’s stock valued at $288,000 after buying an additional 62 shares in the last quarter. Ontario Teachers Pension Plan Board lifted its holdings in shares of Intuitive Surgical by 3.7% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 3,062 shares of the medical equipment provider’s stock worth $1,033,000 after acquiring an additional 109 shares during the period. Finally, US Bancorp DE boosted its position in shares of Intuitive Surgical by 12.7% during the 4th quarter. US Bancorp DE now owns 69,919 shares of the medical equipment provider’s stock worth $23,588,000 after acquiring an additional 7,880 shares in the last quarter. 83.64% of the stock is owned by institutional investors.

Insider Activity

In related news, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the transaction, the senior vice president now owns 3,001 shares in the company, valued at $1,461,006.84. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, insider Mark Brosius sold 2,115 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the sale, the insider now owns 295 shares of the company’s stock, valued at approximately $145,113.45. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the transaction, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. The disclosure for this sale can be found here. In the last three months, insiders have sold 53,120 shares of company stock valued at $25,528,753. 0.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ISRG. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $380.00 to $510.00 in a research report on Friday, August 2nd. Truist Financial raised their price objective on Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Citigroup boosted their target price on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Morgan Stanley lifted their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $446.45.

Intuitive Surgical Trading Down 0.8 %

Shares of ISRG opened at $486.20 on Friday. The company has a market capitalization of $172.46 billion, a PE ratio of 87.76, a PEG ratio of 5.41 and a beta of 1.39. The stock’s 50-day moving average price is $468.01 and its two-hundred day moving average price is $424.86. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same period in the prior year, the business posted $1.18 earnings per share. The firm’s revenue was up 14.5% on a year-over-year basis. Equities research analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.